Anamar team

Ulf Ljungberg, PhD, CEO – Dr. Ljungberg joined AnaMar in October 2015 as Chief Executive Officer. He has long experience from Life science in executive management, licensing/business development and marketing/sales positions in various countries in big pharma and as CEO of biotech start-ups.

Göran Tornling, MD, PhD, CMO – Dr. Tornling joined AnaMar as Chief Medical Officer in December 2014. He brings 15 years of industry experience of clinical drug development, translational medicine, strategy development and senior leadership roles from AstraZeneca. Prior to AnaMar, Dr. Tornling served as VP/CMO at Biolipox AB and EVP/CMO/Head R&D at Orexo AB.

Denise Goode, BSc, ACA (ICAEW), MIoD, VP Business Development – Mrs. Goode has extensive financial, commercial and industry dealmaking experience. She has served in senior leadership positions at Astra Zeneca. In 2014, she established QED Life Sciences Limited, a consultancy business through which she currently advises and supports the strategic direction of biotech clients. Currently, she is a senior advisor to Domainex Limited.

Gunilla Ekström, PhD, VP of R&D – Dr. Ekström joined AnaMar in March 2003 as vice president of research and development. Prior to AnaMar, Dr. Ekström has worked in a broad range of different roles as scientist and manager at AstraZeneca and Active Biotech and has today more than 25 years of experience in drug discovery and development.

Lars Pettersson, PhD, Senior Scientist – Dr. Pettersson joined AnaMar in March 2011 and is responsible for the medicinal chemistry and intellectual property related activities. He has more than 20 years of drug discovery experience, having served in a number of leadership roles at AstraZeneca, Active Biotech and Arcadia Pharmaceuticals.

Christina Wenglén, PhD, Senior Scientist – Dr. Wenglén joined AnaMar in March 2007 and is responsible for the pharmacology in the context of fibrotic and inflammatory diseases. Dr. Wenglén has previously conducted research at the Department of Cell and Molecular Biology, Lund University, focusing on extracellular matrix biology and rheumatic diseases.

Helena Arozenius, MSc, Project Manager – Mrs. Arozenius joined AnaMar in February 2005 and is responsible for the non-clinical development including manufacturing activities. She has over 10 years of experience, including different roles with increasing responsibility. Prior to AnaMar, Ms. Arozenius spent 6 years at Active Biotech as research scientist.